GRANULES INDIA LIMITED
|
|
- Nelson Singleton
- 6 years ago
- Views:
Transcription
1 Independent Equity Research PHARMACEUTICALS BSE Scrip Code: CMP Rs Feb 2012 Vertically intergrated and present across the pharma manufacturing value chain Granules India Limited (Granules) is a pharamaceutical manufacturing company which produces Active Pharmaceutical Ingredients (APIs), Formulation Intermediates (PFIs) and Finished Dosage (FDs) which offers its customers flexibility and choice. Granules is among the top global manufacturers of Paracetamol and Ibuprofen (APIs) and also manufactures single and multiple - active PFIs. The company also has its own Abbreviated New Drug Applications (ANDAs) and dossiers which enables MNC pharma companies to quickly enter the market instead of filing their own applications. Bright outlook due to buoyancy in pharma sector but New Drug pricing policy is a concern CARE Research believes buoyancy in Indian Pharma sector to remain intact but the industry may face pricing pressure from the new drug pricing policy, although the risk for Granules is majorly mitigated on account of high contribution of exports. Key concerns Exchange rate volatility Rising input costs Stiff competition from other Asian countries for manufacture of APIs High dependence on two products (Paracetamol and Ibuprofen) Valuations Granules is currently trading at trailing P/E and EV/EBITDA multiples of 7.2x and 4.9x, respectively. 1
2 CARE HISTORY AND BACKGROUND Background Granules was incorporated in 1984 and is Hyderabad based pharmaceutical company manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosage (FDs). Granules is among the top global manufacturers of Paracetamol and Ibuprofen (APIs) and also manufactures single and multiple-active PFIs. The company also has a dedicated FD plant with a capacity to produce 18 billion tablets per annum. In July 2011, Granules entered the contract manufacturing sector by signing a JV with Ajinomoto OmniChem forming Granules-OmniChem Private Limited. The new entity will initially focus on APIs and intermediates in the cardiovascular, central nervous system (CNS) and oncology therapeutic sectors for patented, brand name products. Operations Granules has manufacturing facilities at Bonthapally, Gagillapur and Jeedimetla (all on outskirts of Hyderabad) in India; and Jingmen and Hubei in China. The company has capacity of 15,200 MTPA for API, 8,400 MTPA for PFI and six billion tablets per annum for FD. The PFI facility in Gagillapur is the largest PFI facility in the world. The facilities have received approval from U.S.FDA, Infarmed, WHO GMP and Australian TGA amongst others. The company is carrying out capacity expansion at Galillapur FD facility from six to 18 billion tablets per annum, at Gaillapur PFI facility from 7,200 MTPA to 16,400 MTPA and is debottlenecking capacity at API facility at Jeedimetla. Industry Segments Source: Company 2
3 Granules historically got majority of its revenues from the API segment. But gradually, with the expansion of PFI and FD segments the revenue mix is shifting towards them. Exports contributed about 83% of sales for Granules in FY11 compared to 80% in FY10. Granules: Industry Segments Source: Company and CARE Equity Research Granules: Operational Performance (In Rs crore) Product FY08 FY09 FY10 FY11 API PFI FD Total sales Source: Company and CARE Equity Research 3
4 CARE Granules: Peer comparison (FY11) Units Granules Elder Pharma Dishman Pharma Strides Acrolab Net operating income Rs. Crores ,060 1,761 EBITDA Rs. Crores PAT Rs. Crores Growth in net operating income % 2% 33.0% 13.0% 24.0% EBITDA Margin % 11.4% 18.5% 19.1% 22.2% PAT Margin % 4.5% 6.6% 7.7% 8.0% RoCE % 10.5% 4.2% 4.6% 4.0% RoE % 10.4% 10.5% 9.3% 9.1% Price/Earnings (P/E) Ratio times Price/Book Value(P/BV) times Enterprise Value (EV)/EBITDA times Source: CapitalLine and CARE Equity Research 4
5 CONSOLIDATED FINANCIAL PERFORMANCE AND ANALYSIS Top line remains almost flat in FY11 Revenue grew from Rs crore to Rs crore in FY11. Sales for the API division which contributed 37% of revenue in FY11 were flat due to higher requirement for captive consumption from tablets and due to a global Paracetamol inventory correction. The small growth in revenue was mainly fuelled by a 170% growth in PFI division. Slow growth in top line coupled with higher raw material prices hurts profitability margins The operating profit for the company decreased from Rs crore in FY10 to Rs crore in FY11. The EBITDA margins for the company decreased 190 basis points in FY11 on account of higher-than-proportionate increase in the raw material prices. Raw materials constitute about 62% of the total expense base. EPS shows de-growth of 9.7% in FY11 over FY10 Net profit for the company decreased by 9.3% in FY11 over FY10 on account of increase of raw material prices due to increase in crude oil prices and government regulations in China. Even the EPS decreased in tandem with the Net Profit and recorded decrease of about 9.7% in FY11 over FY10 after showing growth of about 279.6% in FY10 over FY09. Granules: Consolidated Financial Performance (FY07-11) (Rs. Crores) FY07 FY08 FY09 FY10 FY11 Net operating income EBITDA PAT Fully Diluted EPS* (Rs.) EBITDA margins 18.1% 12.7% 11.2% 13.3% 11.4% PAT margins 5.4% 3.3% 1.8% 5.1% 4.5% Source: Company and CARE Research 5
6 CARE EXPANISONS, NEW INITIATIVES AND CONCERNS Expansion plans and initiatives In July 2011, Granules entered the contract manufacturing sector by signing a JV with Ajinomoto OmniChem and decided to form Granules-OmniChem Private Limited, a 50:50 joint venture company. The new entity will deliver value through a unique contract manufacturing platform by leveraging Granules technological capabilities and efficient processes and OmniChem s extensive product portfolio and existing customers. A greenfield facility will be set up in the Pharmacity SEZ Zone in Vishakhapatnam. The construction of the facility is expected to begin in November 2011 and commercial production will commence in January As per the company, the JV will initially focus on APIs and intermediates in the cardiovascular, central nervous system (CNS) and oncology therapeutic sectors for patented, brand name products. The JV will also work on second-generation manufacturing processes and will develop new chemical entities in the future. The company is scaling up the FD facility in Gagillapur which will increase the capacity from 6 bn doses to 18 bn doses. The expansions are expected to be completed by March The company has added two more workshops at the PFI facility in Gagillapur Module C and D to enhance the capacity by 8,000 tpa and 1,200 tpa respectively. Module-D became operational in June 2011 and Module-C will be operational by March As per the management, Granules de-bottlenecked capacities through an operational excellence programme at the API facility in Jeedimetla which enhanced production capacity of Guaifenesin and Metformin with minimal investments. Granules is also building a new, state-of-the-art (fully-automated) warehouse at Gagillapur to support these expansions. The facility will be ready by mid Key concerns On account of high contribution of exports to the total revenue, the company is exposed to huge currency fluctuation risks. Rising input costs especially oil prices may further impact margins. As about 83% of revenue in FY11 came from export market, the company is in direct competition from other Asian countries for manufacture of APIs. Any failure of quality control tests can impact the future growth prospects. High dependence on a single product (Paracetamol and Ibuprofen); however the company has been de-risking by diversifying its product base and increasing contribution of FD s in the revenue mix. 6
7 SECTOR OUTLOOK Sector outlook The global pharmaceutical market grew 4.1% in 2010 to reach US$856 bn. The market is expected to grow approximately 28% by 2015 to reach US$1.1 tn. Market growth will be driven by a continuing shift to generics and the rapid growth of pharmerging markets. In addition, drugs in the diabetic and oncology therapeutic sectors will grow more rapidly than other sectors. In order to take advantage of the market situation, pharmaceutical companies will need to strengthen production capabilities to meet demand and streamline their supply chain to meet the dynamics of each unique market. India s pharmaceutical market is one of the fastest-growing globally and is estimated to rise from US$10 bn in CY10 to US$17.5 bn in CY14 (14.5% CAGR). The Indian pharma market is now the third-largest in the world in terms of volume and 14 th largest in terms of value thereby accounting for around 10% of world s production by volume and 2% by value due to lower prices. The industry now produces about 500 bulk drugs (APIs) and almost entire range of formulations related to all major therapeutic groups requiring complex manufacturing technologies. This is supported by availability of strong scientific and technical manpower backed by pioneering work done in process development. Exports constituted around 42% of the industry s FY10 sales and have shown a robust growth of nearly 19% per annum over the five-year period ending FY10. Of the total exports, formulations represented approximately 60% while API accounted for the balance 40% in FY10. The share of exports to regulated markets of North America and Europe was 24% and 21% respectively in FY10 and the same has seen an increasing trend over the past few years. This can primarily be attributed to increasing genericization in the regulated markets and growing trend in outsourcing of pharmaceutical production by global pharma companies to low-cost destinations like India. Key segments of the Indian market include formulations, bulk drugs and contract research and manufacturing services. Geographically, the global pharmaceutical market can be classified into regulated markets and less-regulated markets depending upon the level of regulation pertaining to drug quality and patents. The industry is highly fragmented with around 20,000 odd players of which approximately 250 medium to large corporations control about 70% of the total domestic market. In addition there is severe price competition coupled with government price control in many drugs. The top-end of the market is dominated by the organized sector with key players which include domestic pharmaceutical companies and MNCs. The unorganized sector with large number of manufacturers faces intense competition and also deals with spurious drug manufacturers that hamper the overall credibility of the industry. While the growing share of generics in the developed markets and the opportunity from Contract Research and 7
8 CARE Manufacturing Services (CRAMS) have been the primary drivers for exports, changing demographics and growth in chronic therapies have been the major factors contributing to the domestic market growth. The domestic pharma market has grown steadily at a CAGR of around 8% in the past five years. In addition, the score on demand is boosted by the high inelasticity between cost and price in most drugs while penetration of pharmaceutical products in India remains low compared to global average. Also, there are no direct substitutes for pharma products and the industry remains immune against any economic cyclicality or interest rate fluctuations. The Indian pharma market is quite regulated when it comes to the formulation business for both the exports and domestic market. Indian manufacturers have to get their manufacturing units USFDA approved if they are exporting drugs to the US which is the world s largest pharmaceutical market. The Japanese and European markets also have their own stringent laws for exporters creating a huge entry barrier for new players. Moreover, branded drugs are protected by patent laws while generic drugs require the incumbent to have specialized process reengineering technique which is unique to each drug. Strong distribution network is another important parameter in the formulation business for the drugs to reach every hospital, medical practitioner and druggist in every part of the country. Certain generic drugs have brand name advantage (branded generics) while branded drugs have patent protection. The formulations market is quite fragmented and top 5 players control less than 20% of the market share. Competition is intense in the genericgeneric and Over-the-counter (OTC) business which have number of players with pressure on pricing. In the domestic market there is not much of an import threat in formulations but in the export market competition from major global generic players is intense. The Indian pharmaceutical industry is mainly regulated on patents, price and quality. Until 2004, the regulatory system in India focused only on process patents. Indian companies thrived during this phase by process reengineering products of global pharmaceutical players and launching them in India. Indian companies gained process chemistry skills, but de-emphasized on research & development for new drug discoveries. From January 2005, India adopted the WTO norms to follow the product patent regime. The Act allowed for only two types of generic drugs in the Indian market: off-patent generic drugs and generic versions of drugs patented before The Amendment grants new patent holders a 20-year monopoly starting on the date the patent was filed and no generic copies can be sold during the duration of the patent. Other regulations like the Drugs and Cosmetic Act regulate the import, manufacture, distribution and sale of drugs in India. The Drug Price Control Order (DPCO) fixes the ceiling price of some life-saving APIs and critical formulations. Currently, a number of bulk drugs and formulations are under the purview of price control. Currently, the government allows 100% FDI under the automatic route in drugs and pharma sector. 8
9 CONSOLIDATED FINANCIAL SUMMARY Rs. Crores FY07 FY08 FY09 FY10 FY11 Income Statement Net operating income EBITDA Depreciation and amortisation EBIT Interest PBT Ordinary PAT (After minority interest) PAT (After minority interest) Fully Diluted Earnings Per Share* (Rs.) Dividend, including tax * Calculated based on ordinary PAT on Current Face Value of Rs. 10/- per share Balance sheet Net worth (incl. Minority Interest) Debt Deferred Liabilities / (Assets) Capital Employed Net Fixed Assets (incl. Capital WIP) Investments Loans and Advances Inventory Receivables Cash and Cash Equivalents Current Assets, Loans and Advances Less: Current Liabilities and Provisions Total Assets Ratios Growth in Operating Income 46.5% 5.7% 63.4% 1.6% Growth in EBITDA 2.4% -6.8% 95.5% -13.0% Growth in PAT -9.8% -44.4% 371.5% -9.3% Growth in EPS -10.4% -33.7% 279.6% -9.7% EBITDA Margin 12.7% 11.2% 13.3% 11.4% PAT Margin 3.3% 1.8% 5.1% 4.5% RoCE 7.8% 6.4% 12.8% 10.5% RoE 5.4% 3.0% 12.8% 10.4% Debt-Equity (times) Interest Coverage (times) Current Ratio (times) Inventory Days Receivable Days Price / Earnings (P/E) Ratio Price / Book Value(P/BV) Ratio Enterprise Value (EV)/EBITDA Source: CapitalLine and CARE Equity Research 9
10 CARE DISCLAIMER DISCLOSURES Each member of the team involved in the preparation of this grading report, hereby affirms that there exists no conflict of interest that can bias the grading recommendation of the company. This report has been sponsored by the Bombay Stock Exchange (BSE). DISCLAIMER This BSE sponsored report is prepared by CARE Research, a division of Credit Analysis & REsearch Limited [CARE]. CARE Research has taken utmost care to ensure accuracy and objectivity while developing this report based on information available in public domain or from sources considered reliable. However, neither the accuracy nor completeness of information contained in this report is guaranteed. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report can be construed as either investment or any other advice or any solicitation, whatsoever. The subscriber / user assumes the entire risk of any use made of this report or data herein. CARE specifically states that it or any of its divisions or employees do not have any financial liabilities whatsoever to the subscribers / users of this report. This report is for personal information only of the authorised recipient in India only. This report or part of it should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person or published or copied for any purpose. Credit Analysis and Research Limited proposes, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus ( DRHP ) with the Securities and Exchange Board of India (the SEBI ). The DRHP is available on the website of SEBI at as well as on the websites of the Book Running Lead Managers at and Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled Risk Factors of the DRHP. [ This press release is not for publication or distribution to persons in the United States, and is not an offer for sale within the United States of any equity shares or any other security of Credit Analysis and Research Limited. Securities of Credit Analysis and Research Limited, including its equity shares, may not be offered or sold in the United States absent registration under U.S. securities laws or unless exempt from registration under such laws. ] Published by Credit Analysis & REsearch Ltd., 4th Floor Godrej Coliseum, Off Eastern Express Highway, Somaiya Hospital Road, Sion East, Mumbai CARE Research is not responsible for any errors or omissions in analysis/inferences/views or for results obtained from the use of information contained in this report and especially states that CARE (including all divisions) has no financial liability whatsoever to the user of this product. This report is for the information of the intended recipients only and no part of this report may be published or reproduced in any form or manner without prior written permission of CARE Research. 10
11 ABOUT US Credit Analysis & REsearch Ltd. (CARE) is a full service rating company that offers a wide range of rating and grading services across sectors. CARE has an unparallel depth of expertise. CARE Ratings methodologies are in line with the best international practices. CARE Research CARE Research is an independent research division of CARE Ratings, a full-service rating company. CARE Research is involved in preparing detailed industry research reports with 5-year demand and 2-year profitability outlook on the industry besides providing comprehensive trend analysis and the current state of the industry. CARE Research currently offers reports on more than 26 industries which are updated on a monthly/quarterly basis. Subscribers can access CARE Research reports online. CARE Research also offers research that is customized to client requirements. Customized Research involves business analysis and position in the market, financial analysis and market sizing etc. HEAD OFFICE Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai Tel: , Fax: NEW DELHI 3rd Floor, B -47, Inner Circle, Near Plaza Cinema, Connaught Place, New Delhi Tel: / / AHMEDABAD 32, Titanium, Prahaladnagar Corporate Road, Satellite, Ahmedabad Tel: KOLKATA 3rd Floor, Prasad Chambers (Shagun Mall Building), 10A, Shakespeare Sarani, Kolkata Tel: / / HYDERABAD 401, Ashoka Scintilla, , Himayat Nagar, Hyderabad Tel: CHENNAI Unit No. O-509/C, Spencer Plaza, 5th Floor, No. 769, Anna Salai, Chennai Tel: / BANGLORE Unit No. 8, I floor, Commander's Place, No. 6, Raja Ram Mohan Roy Road, (Opp. P F Office), Richmond Circle, Bangalore Tel: Published on behalf of The Stock Exchange Investors' Protection Fund Bombay Stock Exchange Ltd. P J Towers, Dalal Street, Mumbai. Tel: /
ENGLISH INDIAN CLAYS LIMITED Industry: Commodity Chemicals/Diversified BSE Scrip Code:
CARE Independent Equity Research ENGLISH INDIAN CLAYS LIMITED Industry: Commodity Chemicals/Diversified BSE Scrip Code: 526560 ENGLISH INDIAN CLAYS LTD. CMP Rs. 33.4 1 21 st November 2011 Update for Quarter
More informationSINTEX INDUSTRIES LIMITED
EQUI-GRADE Analytical Power for Investment Decisions Sintex Industries Limited Plastics and Textiles SINTEX INDUSTRIES LIMITED December 29, 2011 Very Good Fundamentals; Considerable Upside Potential CMP:
More informationBSE-SME COMPANY RESEARCH REPORT
BSE-SME COMPANY RESEARCH REPORT BRONZE INFRA- TECH LTD. December 19, 2012 www.careratings.com F DISCLOSURES AND DISCLAIMER DISCLOSURES Each member of the team involved in the preparation of this report,
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationUpdate for Quarter and Year ended 31 st March, 2012
Independent Equity Research Other Agricultural Products BSE Scrip Code: 524226 CMP Rs. 20.5 1 July 9, 2012 Update for Quarter and Year ended 31 st March, 2012 Decline in revenue in Q4FY12 For Q4FY12 (refers
More informationD.S. KULKARNI DEVELOPERS LTD REAL ESTATE INDUSTY BSE Scrip Code:
Independent Equity Research D.S. KULKARNI DEVELOPERS LTD REAL ESTATE INDUSTY BSE Scrip Code: 523890 CMP Rs.55 1 July 20, 2012 Update for Quarter and Year ended 31 st March, 2012 Decline in revenue D. S.
More informationBSE-SME COMPANY RESEARCH REPORT
BSE-SME COMPANY RESEARCH REPORT BCB FINANCE LTD. November 27, 2012 www.careratings.com F DISCLOSURES AND DISCLAIMER DISCLOSURES Each member of the team involved in the preparation of this report, hereby
More informationBSE-SME COMPANY RESEARCH REPORT
BSE-SME COMPANY RESEARCH REPORT JUPITER INFOMEDIA LTD. July 5, 2012 F DISCLOSURES AND DISCLAIMER DISCLOSURES Each member of the team involved in the preparation of this grading report, hereby affirms that
More informationRoyal India Corporation Limited BSE Scrip Code:
Royal India Corporation Limited BSE Scrip Code: 512047 Other Apparels & Accessories September 13, 2012 Equity Statistics Current Market Price Rs. 78.1 52 Week High / Low Rs. 97.9/58.5 Market Capitalisation
More informationCMP Rs March 5, 2012
Independent Equity Research SONA KOYO STEERING SYSTEMS LTD SONA KOYO STEERING SYSTEMS LIMITED AUTO PARTS & EQUIPMENT BSE Scrip Code: 520057 CMP Rs.13.3 1 March 5, 2012 Dominant position in the domestic
More informationVolant Textile Mills Ltd BSE Scrip Code:
Volant Textile Mills Ltd BSE Scrip Code: 531865 Textiles October 09, 2012 Equity Statistics Current Market Price Rs. 3.11 52 Week High/Low Rs. 3.55/1.34 Market Capitalisation Rs. Crores 23.31 Free Float
More informationAditya Gears Ltd. BSE Scrip Code:
Aditya Gears Ltd. BSE Scrip Code: 53677 Auto Parts & Equipment March 5, 23 Last Traded Price* Rs. 52 Week High/Low Rs. Market Capitalisation* Free Float Dividend Yield % One Year Regression Beta Equity
More informationS R K Industries Ltd. BSE Scrip Code:
S R K Industries Ltd. BSE Scrip Code: 531307 Textiles March 15, 2013 Equity Statistics Current Market Price Rs. 28.4 52 Week High/Low Rs. 32.65/2.90 Market Capitalisation Rs. Crores 10.71 Free Float Rs.
More informationRating Methodology for Port Projects Background
Rating Methodology for Port Projects Background India has 7,517-km long coastline with 13 major ports and 187 minor/intermediate ports, which handle bulk of India s international trade. The primary responsibility
More informationEquity Statistics Current Market Price Rs Week High/Low Rs /9.01 Market Capitalisation Rs. Crores Dividend Yield %
MILTON PLASTICS LTD BSE Scrip Code: 526143 Containers & Packaging March 14, 2013 Equity Statistics Current Market Price Rs. 9.7 52 Week High/Low Rs. 15.81/9.01 Market Capitalisation Rs. Crores 12.13 Free
More informationIST Ltd BSE Scrip Code:
IST Ltd BSE Scrip Code: 508807 Other Apparels & Accessories September 13, 2012 Equity Statistics Current Market Price Rs. 170.3 52 Week High / Low Rs. 209/124 Market Capitalisation Rs. crores 98.7 Free
More informationKrypton Industries Ltd BSE Scrip Code:
Krypton Industries Ltd BSE Scrip Code: 523550 Auto Tyres & Rubber Products October 19, 2012 Equity Statistics Current Market Price Rs. 14.3 52 Week High/Low Rs. 17.74/11.55 Market Capitalisation Rs. Crores
More informationAmrutanjan Health Care Ltd. BSE Scrip Code:
Amrutanjan Health Care Ltd. BSE Scrip Code: 590006 Pharmaceuticals September 13, 2012 Equity Statistics Current Market Price Rs. 791.2 52 Week High/Low Rs. 881.00/610.10 Market Capitalisation Rs. Crores
More informationIndependent Equity Research LUMAX AUTO TECH LTD LUMAX AUTO TECHNOLOGIES LIMITED AUTO PARTS & EQUIPMENT BSE Scrip Code:
CARE Independent Equity Research LUMAX AUTO TECH LTD LUMAX AUTO TECHNOLOGIES LIMITED AUTO PARTS & EQUIPMENT BSE Scrip Code: 532796 CMP Rs.151.70 1 23 Feb 2012 Wide product portfolio and large client base
More informationLippi Systems Ltd BSE Scrip Code:
Lippi Systems Ltd BSE Scrip Code: 526604 Industrial Machinery October 30, 2012 Equity Statistics Current Market Price Rs. 4.8 52 Week High/Low Rs. 7.24/4.01 Market Capitalisation Rs. Crores 3.4 Free Float
More informationShalimar Wires Industries Ltd. BSE Scrip Code:
Shalimar Wires Industries Ltd. BSE Scrip Code: 532455 Paper Machine Clothing and EMD Wires October 15, 2012 Equity Statistics Current Market Price Rs. 7.61 52 Week High/Low Rs. 14.00/6.72 Market Capitalisation
More informationHawkins Cookers Ltd BSE Scrip Code:
Hawkins Cookers Ltd BSE Scrip Code: 508486 Houseware September 05, 2012 Equity Statistics Current Market Price Rs. 1,667.5 52 Week High / Low Rs. 1759.9/1215 Market Capitalisation Rs. crores 881.7 Free
More informationReligare Technologies Ltd BSE Scrip Code:
Religare Technologies Ltd BSE Scrip Code: 533525 IT Consulting & Software October 15, 2012 Equity Statistics Current Market Price Rs. 17.05 52 Week High/Low Rs. 44.90/13.70 Market Capitalisation Rs. Crores
More informationButterfly Gandhimathi Appliances Ltd. BSE Scrip Code:
Butterfly Gandhimathi Appliances Ltd. BSE Scrip Code: 517421 Household Appliances September 05, 2012 Equity Statistics Current Market Price Rs. 355.0 52 Week High / Low Rs. 420/240 Market Capitalisation
More informationUNIVERSAL CABLES LIMITED
Independent Equity Research ELECTRICAL EQUIPMENTS BSE Scrip Code: 504212 CMP Rs. 46.05 1 15 Feb 2012 Wide product portfolio Universal Cables Limited (UCL) has a range of products including Low Voltage
More informationWires & Fabriks (SA) Limited BSE Scrip Code:
Wires & Fabriks (SA) Limited BSE Scrip Code: 507817 Textiles September 17, 2012 Equity Statistics Current Market Price Rs. 77.0 52 Week High / Low Rs. 106.80/68.50 Market Capitalisation Rs. crores 23.5
More informationKG Denim Ltd BSE Scrip Code:
KG Denim Ltd BSE Scrip Code: 500239 Textiles September 24, 2012 Equity Statistics Current Market Price Rs. 52 Week High / Low Rs. Market Capitalisation Rs. crores Free Float Rs. crores Dividend Yield %
More informationAnkit Metal & Power Ltd BSE Scrip Code:
Ankit Metal & Power Ltd BSE Scrip Code: 532870 Steel- Sponge Iron September 17, 2012 Business Summary Ankit Metal & Power Limited (AMPL), a Kolkata-based company, promoted by Mr Suresh Kumar Patni, is
More informationSignet Industries Ltd BSE Scrip Code:
Signet Industries Ltd BSE Scrip Code: 512131 Comm. Trading & Distribution September 21, 2012 Equity Statistics Current Market Price Rs. 52 Week High / Low Rs. Market Capitalisation Rs. crores Free Float
More informationNirlon Ltd BSE Scrip Code:
Nirlon Ltd BSE Scrip Code: 500307 Misc. Commercial Services September 14, 2012 Equity Statistics Current Market Price Rs. 44.5 52 Week High / Low Rs. 61.75/30.50 Market Capitalisation Rs. crores 319.7
More informationGranules India Ltd. 21 st July, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Granules India Ltd. 21 st July, 2012 CMP Target Price Rs.149.30 Rs.200.00 Granules India is among the leading global manufacturer of highvolume
More informationOMAX AUTOS LIMITED. Independent Equity Research OMAX AUTOS LIMITED. CMP Rs Feb AUTO PARTS & EQUIPMENT BSE Scrip Code:
Independent Equity Research AUTO PARTS & EQUIPMENT BSE Scrip Code: 520021 CMP Rs.43.35 1 23 Feb 2012 Leading supplier for Automobile components; Diversified into railways and home furnishing business Omax
More informationRating Criteria For Small and Medium Enterprises
Rating Criteria For Small and Medium Enterprises Background SME (Small and Medium Enterprises) segment plays a very vital role in the economic development of our nation. Credit risk assessment in this
More informationCARE s FUND CREDIT QUALITY RATING CRITERIA
CARE s FUND CREDIT QUALITY RATING CRITERIA Introduction CARE s fund credit quality ratings are opinions on the overall credit quality of specific Debt Mutual Fund schemes. The ratings capture the fund
More informationBSE-SME COMPANY RESEARCH REPORT
BSE-SME COMPANY RESEARCH REPORT JOINTECA EDUCATION SOLUTIONS LTD. July 23, 2012 F DISCLOSURES AND DISCLAIMER DISCLOSURES Each member of the team involved in the preparation of this grading report, hereby
More informationCARE REVISES THE RATING ASSIGNED TO BANK FACILITIES AND CP/STD OF BOMBAY RAYON FASHIONS LTD. Amount
July 31, 2012 Press Release CARE REVISES THE RATING ASSIGNED TO BANK FACILITIES AND CP/STD OF BOMBAY RAYON FASHIONS LTD. Facilities/Instruments Long-term Bank Facilities Amount Ratings 1 (Rs. crore) 3,167.20
More informationAcrysil Ltd. BSE Scrip Code:
Acrysil Ltd. BSE Scrip Code: 524091 Plastic Products September 14, 2012 Equity Statistics Current Market Price Rs. 131.2 52 Week High / Low Rs. 149/87.35 Market Capitalisation Rs. crores 39.0 Free Float
More informationMahaveer Infoway Ltd BSE Scrip Code:
Mahaveer Infoway Ltd BSE Scrip Code: 590117 IT Consulting & Software October 18, 2012 Equity Statistics Current Market Price Rs. 7.19 52 Week High/Low Rs. 21.15/7.10 Market Capitalisation Rs. Crores 3.96
More informationCARE s Rating Methodology For Banks
CARE s Rating Methodology For Banks CARE's ratings are an opinion on the relative ability and willingness of an issuer to make timely payments on the specific debt obligations over the life of the instrument.
More informationRSWM LIMITED. Independent Equity Research RSWM LIMITED. CMP Rs March 16, TEXTILES BSE Scrip Code:
CARE Independent Equity Research TEXTILES BSE Scrip Code: 500350 CMP Rs.87.5 1 March 16, 2012 Integrated textile player having significant brand awareness RSWM Limited (RSWM) is a leading and integrated
More informationRATING METHODOLOGY FOR DEBT ISSUES OF TOLL ROAD PROJECTS
RATING METHODOLOGY FOR DEBT ISSUES OF TOLL ROAD PROJECTS CARE s rating methodology for debt issues of road projects (RPs) is designed to facilitate appropriate credit risk assessment, keeping in view the
More informationRating Methodology - Port Projects [In supersession of Rating Methodology Port Projects issued in June 2017]
RATING METHODOLOGY - PORT PROJECTS Rating Methodology - Port Projects [In supersession of Rating Methodology Port Projects issued in June 2017] Background India has 7,517-km long coastline with 13 major
More informationIndian CRAMS Industry. Steel. The. otel. Pesticides. Tracto. nking Express Service. Power Generation Pa. Hospital Industry. Express Service Cr
inum Banking Cement Commercial Vehicle Cotton & Cotton Ya Business Process Management (BPM) Construction Educat Chlor-Alkali Renewable Energy Crude Oil Gems & J o Component pparel Industry oal Natural
More informationCARE s Rating Methodology - Wholesale Trading
RATING METHODOLOGY - WHOLESALE TRADING CARE s Rating Methodology - Wholesale Trading [In supersession of CARE s Rating Methodology - Wholesale Trading issued in June 2017] Overview The increase in global
More informationRating Methodology - Private Power Producers
RATING METHODOLOGY - PRIVATE POWER PRODUCERS Rating Methodology - Private Power Producers [In supersession of Rating Methodology - Private Power Producers issued in December 2016] The ongoing liberalisation
More informationGRANULES INDIA STRATEGIC SHIFT
GRANULES INDIA STRATEGIC SHIFT 4 Recommendation BUY STRATEGIC SHIFT CMP (19 Jan 2015) Rs 830 Target Price Rs 1128 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN
More informationCentral Bank of India
Central Bank of India May 25, 2018 Ratings Facilities/Instruments Amount Rating 1 Rating Action Lower Tier II Bond Series XIII - - Withdrawn Details of instruments/facilities in Annexure-1 Detailed Rationale,
More informationBird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
More informationGanapati Builders Limited
Ratings Facilities Ganapati Builders Limited Amount Long term Bank Facilities 8.00 Total December 18, 2017 8.00 (Rupees Eight crore only) Rating 1 CARE B+; Stable (Single B Plus ; Outlook: Stable) Rating
More informationSHIVA INDUSTRIAL SECURITY AGENCY (GUJARAT) PRIVATE LIMITED JANUARY 19, 2017
SHIVA INDUSTRIAL SECURITY AGENCY (GUJARAT) PRIVATE LIMITED JANUARY 19, 2017 Ratings Facilities Amount Long-term Bank Facilities 12.69 Short-term Bank Facilities 1.00 13.69 Total (Rupees Thirteen crore
More informationRating Methodology - Manufacturing Companies
RATING METHODOLOGY - MANUFACTURING COMPANIES Rating Methodology - Manufacturing Companies [In supersession of Rating Methodology - Manufacturing Companies issued in December 2016] Credit analysis of an
More informationServices in MSME Segment
Services in MSME Segment Committed to Assist SMALL business to grow BIG CARE Ratings' products assist MSMEs for Fund Raising: Equity and Debt Availing Favourable Credit Terms Reduce Transaction Costs Self
More informationEQUI-GRADE Analytical Power for Investment Decision
Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 EQUI-GRADE Analytical Power for Investment Decision Iron & Steel and Lighting Products November 28, 2013 Good Fundamentals,
More informationCARE s Fund Credit Quality Rating Criteria
FUND CREDIT QUALITY RATING CRITERIA CARE s Fund Credit Quality Rating Criteria Introduction CARE s fund credit quality ratings are opinion on the overall credit quality of specific Debt Mutual Fund schemes.
More informationICICI PRUDENTIAL MUTUAL FUND (Revised) August 08, 2018
: ICICI PRUDENTIAL MUTUAL FUND (Revised) August 08, 2018 Scheme Name Scheme Tenure 1 Action Series VIII Plan F * Close Ended 683 Days [Triple A mfs (Structured Obligation)] Reaffirmed Details of /Facilities
More informationDIL Ltd. Pharmaceuticals. Company Overview. Company Fundamentals. CMP Rs
Pharmaceuticals September 26, 2012 CMP Rs. 700.4 BSE Code 506414 BSE ID DIL High/Low 1Y (Rs.) 748.2 / 373.9 Average Volume (3M) 579.8 Market Cap (Rs. Cr.) 161.1 Shareholding % Jun-12 Mar-12 Promoters 63.20
More informationRating Methodology - Banks
RATING METHODOLOGY - BANKS Rating Methodology - Banks [In supersession of CARE s Rating Methodology - Banks issued in December 2016] CARE's ratings are an opinion on the relative ability and willingness
More informationICICI Prudential Capital Protection Oriented Fund III-XII. July 26, 2017
IIIXII July 26, 2017 Ratings Facilities/Instruments Scheme Type Ratings 1 Remarks III Plan B, E, G and H IV Plan A, C, D, F and G V Plan A and C V Plan B, DF* VI Plan AH VII Plan AH VIII Plan AJ IX Plan
More informationClaims Paying Ability - Insurance Companies
CLAIMS PAYING ABILITY - INSURANCE COMPANIES Claims Paying Ability - Insurance Companies [In supersession of Claims Paying Ability - Insurance Companies issued in June 2017] CARE s Claims Paying Ability
More informationL&T Infrastructure Finance Company Limited
Ratings Facilities L&T Infrastructure Finance Company Limited December 07, 2017 Amount (Rs. crore) Rating 1 Rating Action Commercial Paper (for IPO financing) - - Withdrawn Details of instruments/facilities
More informationJenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationKPIT Cummins Infosystems Ltd. BSE Scrip Code:
KPIT Cummins Infosystems Ltd. BSE Scrip Code: 532400 IT Consulting & Software September 14, 2012 Equity Statistics Current Market Price Rs. 127.9 52 Week High / Low Rs. 142.00/68.30 Market Capitalisation
More informationRating Methodology: Factoring Linkages in Ratings (Parent-Subsidiary Link, Group Support, Government Support)
FACTORING LINKAGES IN RATINGS Rating Methodology: Factoring Linkages in Ratings (Parent-Subsidiary Link, Group Support, Government Support) [In supersession of CARE s Rating Methodology: Factoring Linkages
More informationCadila Healthcare Ltd.
Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:
More informationLara Drugs Private Limited October 09, 2018
Rating Facilities Lara Drugs Private Limited October 09, 2018 Amount Long-term Bank Facilities 7.40 Total 7.40 (Rupees seven core and forty lakh only) Details of facilities in Annexure-1 Rating 1 CARE
More informationHINDUSTAN CONSTRUCTION COMPANY LIMITED
HINDUSTAN CONSTRUCTION COMPANY LIMITED Ratings Facilities/ Instruments Amount (Rs. crore) Rating 1 * Remarks Long-term Facilities (Term Loans) 2,084.28 (reduced from 2,358.75) Short-term Facilities 875.00
More informationMount Shivalik Industries Ltd BSE Scrip Code:
Mount Shivalik Industries Ltd BSE Scrip Code: 507522 Breweries & Distilleries October 11, 2012 Equity Statistics Current Market Price Rs. 38 52 Week High/Low Rs. 49.30/19.00 Market Capitalisation Rs. Crores
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares
More informationBinani Cement Limited
Binani Cement Limited July 11, 2018 Ratings Amount Rating 1 Long term Bank 2,304.27 CARE D; ISSUER (Single D; ISSUER Short term Bank 436.00 ) Total facilities 2,740.27 (Rupees Two Thousand Seven Hundred
More informationRock Regency Hotels Private Limited June 25, 2018
Rating Facilities Rock Regency Hotels Private Limited June 25, 2018 Amount Long term Bank Facilities 4.11 Total 4.11 (Rupees Four crore and eleven lakh only) Details of instruments/facilities in Annexure-1
More informationCredit Analysis & Research Limited. Complete definitions of the ratings assigned are available at and other CARE publications
Neuland Laboratories Limited Ratings Facilities Amount (Rs. crore) Ratings 1 Remarks Long-term Bank Facilities 205.51 (enhanced from Rs. 175.51 crore ) CARE BBB- (Triple B Minus) Reaffirmed Short-term
More informationSuryachakra Power Corporation Ltd BSE Scrip Code:
Suryachakra Power Corporation Ltd BSE Scrip Code: 532874 Power-Generation/Distribution October 12, 2012 Equity Statistics Current Market Price Rs. 1.73 52 Week High/Low Rs. 10.67/0.94 Market Capitalisation
More informationEMCURE PHARMACEUTICALS LIMITED
EMCURE PHARMACEUTICALS LIMITED Ratings Facilities Amount (Rs. crore) Long-term Bank Facilities 507.89 (reduced from 542.80) Short-term Bank Facilities 115.04 (reduced from 117) Long/Short-term Bank Facilities
More informationC.M.Builds Private Limited November 03, 2017
Rating Facilities Long-term Bank Facilities C.M.Builds Private Limited November 03, 2017 Amount 10 Total Facilities (Rupees Ten crore only) Details of instruments/facilities in Annexure-1 10 Rating 1 CARE
More informationPanyam Cements and Mineral Industries Limited January 6, 2017
Ratings Facilities Panyam Cements and Mineral Industries Limited January 6, 2017 Amount Long-term Bank Facilities 30.00 Short-term Bank Facilities 9.32 Rating 1 CARE BB-; Stable (Double B Minus; Outlook:
More informationRaipur Power and Steel Limited August 21, 2018
Ratings Long term Bank Short term Bank Total 354.65 (Rupees Three hundred fifty four crore and sixty five lakhs only) Details of instruments/facilities in Annexure-1 Raipur Power and Steel Limited August
More informationMillenium Steel India Private Limited
Millenium Steel India Private Limited Ratings Facilities Amount Long term Bank Facilities 6.88 Short term Bank Facilities 26.00 Total Facilities February 28, 2018 32.88 (Rs. Thirty Two crore and Eighty
More informationCompany Fundamentals
IT Software Products November 16, 2012 *CMP Rs.0.24 BSE Code 532403 BSE ID 4THGEN High/Low 1Y (Rs.) 0.62/0.22 Average Volume (3M) 6457 Market Cap (Rs. Cr.) 1 Shareholding % Sep-12 Jun-12 Promoters 15.32
More informationServices in MSME Segment
Services in MSME Segment Committed to Assist SMALL business to grow BIG CARE Ratings' products assist MSMEs for Fund Raising: Equity and Debt Availing Favourable Credit Terms Reduce Transaction Costs Self
More informationRAYMOND LIMITED. (Rs. crore) (Rs. crore)
RAYMOND LIMITED Amount (Rs. crore) 1 Remarks Long-term Bank 1,585 CARE AA- Short-term Bank 475 (enhanced from Rs.370.95) Total 2,060 CARE A1+ [A One Plus] Non Convertible Debentures 175 CARE AA- Commercial
More informationUnidrug Innovative Pharma Technologies Limited
Ratings Unidrug Innovative Pharma Technologies Limited Facilities Amount (Rs. crore) Ratings 1 Remarks Long-term Bank Facilities 7.10 (reduced from 7.30) CARE BB (Double B) Revised from CARE BB- (Double
More informationColourtex Industries Private Limited
Colourtex Industries Private Limited January 18, 2017 Ratings Facilities Long-term Bank facilities Long-term/Short-term Bank facilities Amount 50.25 (reduced from 71.14) 370.00 420.25 Total Facilities
More informationCoimbatore Capital Limited January 6, 2017
Ratings Facilities Coimbatore Capital Limited January 6, 2017 Amount Short-term Bank Facilities 37 37 Total Facilities (Rupees Thirty Seven crore only) Details of instruments/facilities in Anneuxre-1 Rating
More informationGlance Finance Ltd. Other Financial Services. . Company Overview. Company Fundamentals. Key Strengths. CMP Rs BSE Code BSE ID
Other Financial Services Nov 15, 2012 CMP Rs. 19.55 BSE Code 531199 BSE ID GLANCE High/Low 1Y (Rs.) 35.15/ 16.55 Average Volume (3M) 279 Market Cap (Rs. Cr.) 6 Shareholding % Sep-12 Jun-12 Promoters 74.83
More informationKripa Telecom. March 23, Rating 1. CARE A4; ISSUER NOT COOPERATING* (A four)
Ratings Facilities Amount Long term Bank Facilities 3 Short-term Bank Facilities 6 Total 9 (Rupees Nine crore only) Details of instruments/facilities in Annexure-1 Detailed Rationale & Key Rating Drivers
More informationHetero Drugs Limited
Hetero Drugs Limited January 17, 2017 Ratings Long-term Bank Long-term/ Short-term Bank Amount 355 (enhanced from 311.10) 320 Rating 1 CARE A+; Stable (Single A Plus; Outlook: Stable) CARE A+; Stable/
More informationL&T Infrastructure Finance Company Limited
Ratings L&T Infrastructure Finance Company Limited July 23, 2018 Facilities Amount(Rs. crore) Rating 1 Rating Action Commercial Paper (IPO Financing) - - Withdrawn Details of instruments/facilities in
More informationMargin (%) PAT (Rs cr)
4 Recommendation HOLD Reiterating positive outlook CMP (27/7/2015) Rs. 115 Target Price Rs. 125 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN IN Market Cap
More informationRating Methodology - Toll Road Projects [In supersession of Rating Methodology - Toll Road Projects issued in June 2017]
[In supersession of Rating Methodology - Toll Road Projects issued in June 2017] CARE s rating methodology for debt issues of road projects is designed to facilitate appropriate credit risk assessment,
More informationAU FINANCIERS (INDIA) LIMITED
AU FINANCIERS (INDIA) LIMITED Ratings Instrument Amount (Rs. crore) Ratings 1 Remarks Long-term Bank Facilities 1,100 CARE A [Single A] Non Convertible Debenture 45 CARE A [Single A] Subordinated Debt
More informationGayatri Projects Limited
Gayatri Projects Limited March 12, 2018 Ratings Amount Long-term Bank 2138.03 Long-term/Short-term Bank 4594.03 6732.06 (Rupees Six thousand Seven Total hundred Thirty Two crore and Six lakh only) Details
More informationKey financials (YE Mar) FY13 FY14 FY15e FY16e FY17e
28 October 214 Granules India Key takeaways expect it to rise to 4% in FY17. with higher-than-current margins of Granules. Riding a multi-year growth wave; initiating with a Buy India I Equities Successful
More informationICICI Securities Primary Dealership Ltd.
Ratings Instrument Amount (Rs. crore) Tier II Bonds 50 (Rupees Fifty Crore Only) Details of instruments/facilities in Annexure-1 ICICI Securities Primary Dealership Ltd. May 09, 2018 Rating 1 CARE (Triple
More informationDIGAMBER CAPFIN LIMITED
DIGAMBER CAPFIN LIMITED Rating Facilities Amount (Rs. crore) Rating 1 Remarks Long-term Bank Facilities 30 CARE BB (Double B) Assigned Rating Rationale The rating is primarily constrained by the small
More informationRating Methodology - Housing Finance Companies (HFCs)
RATING METHODOLOGY - HOUSING FINANCE COMPANIES (HFCS) Rating Methodology - Housing Finance Companies (HFCs) [In supersession of CARE s Rating Methodology - Housing Finance Companies (HFCs) issued in June
More informationHDFC Bank Ltd. May 8, 2017
HDFC Bank Ltd. May 8, 2017 Rating Facilities/Instruments Amount (Rs. crore) Rating 1 Rating Action Certificate of Deposits 40,000 (enhanced from 25,000) CARE A1+ (A One Plus) Reaffirmed Additional Tier
More informationK.P. CHACKO & SONS JUNE 30, 2017
Ratings K.P. CHACKO & SONS JUNE 30, 2017 Facilities Amount Rating 1 Long-term Bank Facilities 17 CARE B+; Stable (Single B Plus ; Outlook: Stable) Rating Action Assigned Total 17 (Rupees Seventeen crore
More informationSKS Textiles Limited (NSE SME)
SKS Textiles Limited (NSE SME) IPO Fact Sheet SKS Textiles Ltd. Opening Date January 9 th, 2018 Closing Date January 11 th, 2018 BRLMs Aryaman Financial Services Issue Size Rs. 13.32 Crores Shares 8.88
More information